Precision NeuroMed Achieves Orphan Drug Status for Glioblastoma Treatment Innovations Precision NeuroMed has been awarded the FDA Orphan Drug Designation for its novel glioblastoma treatment, showcasing advancements in drug delivery systems for better patient outcomes.

Precision NeuroMed Achieves Orphan Drug Status for Glioblastoma Treatment Innovations #USA #Redwood_City #Glioblastoma #FDA_Orphan_Drug #Precision_NeuroMed